Moderna, Inc. MRNA
198.88
4.06
2.08%
as of 25 Sep
- Market cap
- $78.8B
- P/E
- 0.0×
Follow MRNA
Indexes
indicate stock being part of an index
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (39.00%) | (36.56%) | (28.87%) | (29.32%) |
+8 more TTM periods Free account |
|
| (27.43%) | (26.41%) | (21.31%) | (22.31%) | ||
ROIC |
(93.47%) | (76.00%) | (55.51%) | (44.61%) | |
Return on Tangible Assets |
(59.01%) | (58.49%) | (42.18%) | (44.24%) | |
Average Days of Receivables |
2.79 | 11.65 | 34.55 | 171.05 | |
Free Cash Flow per Share |
(3.13) | (4.06) | (5.33) | (6.83) | |
Free Cash Flow |
(1,244.00) | (1,603.00) | (2,075.00) | (2,663.00) | |
Capital Expenditures |
(171.00) | (137.00) | (202.00) | (685.00) | |
Piotroski F-Score |
1.00 | 1.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(8.59%) | (11.09%) | (12.44%) | (14.27%) | |
Accounts Receivable Turnover |
84.08 | 29.87 | 7.17 | 1.71 | |
Accounts Payable Turnover |
9.98 | 8.96 | 2.40 | 3.61 | |
Inventory Turnover |
6.57 | 12.65 | 6.43 | 3.10 | |
Average Days of Payables |
35.71 | 33.91 | 133.30 | 84.38 | |
Days of Inventory on Hand |
59.87 | 30.75 | 64.34 | 104.92 | |
Tax Rate |
0.02 | 0.02 | 0.02 | (0.01) | |
Research and Development Expense of Revenue |
129.08% | 131.46% | 161.11% | 155.87% | |
Selling, General and Administrative Expense of Revenue |
43.31% | 44.00% | 52.37% | 47.54% | |
Share Based Compensation of Revenue |
20.74% | 21.21% | 24.85% | 21.24% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.34 | 0.46 | 0.66 | 0.63 | |
Depreciation/Fixed assets |
0.09 | 0.08 | 0.07 | 0.06 | |
Capex/Depreciation |
(0.90) | (0.78) | (1.36) | (5.07) | |
Revenue per Share |
5.60 | 5.63 | 5.00 | 5.72 | |
Operating CF per Share |
(2.70) | (3.71) | (4.81) | (5.07) | |
Capex per Share |
(0.43) | (0.35) | (0.52) | (1.76) | |
Capex to Sales |
0.08 | 0.06 | 0.10 | 0.31 | |
Net Profit Margin |
(141.43%) | (143.55%) | (145.16%) | (139.61%) |
Columns are period end dates